Yip TCF et al. Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B. (Abstract LB-03),Choi J et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019;5:30-6.
Fidaxomicine en vancomycine verlagen 'C. difficile'-uitscheiding en contaminatie van de omgeving
aug 2022 | Bacteriële infecties